LLY

1,006.74

-1.12%↓

JNJ

229.99

-0.1%↓

ABBV

210.58

+1.02%↑

UNH

400.55

-0.16%↓

AZN

185.18

-0.81%↓

LLY

1,006.74

-1.12%↓

JNJ

229.99

-0.1%↓

ABBV

210.58

+1.02%↑

UNH

400.55

-0.16%↓

AZN

185.18

-0.81%↓

LLY

1,006.74

-1.12%↓

JNJ

229.99

-0.1%↓

ABBV

210.58

+1.02%↑

UNH

400.55

-0.16%↓

AZN

185.18

-0.81%↓

LLY

1,006.74

-1.12%↓

JNJ

229.99

-0.1%↓

ABBV

210.58

+1.02%↑

UNH

400.55

-0.16%↓

AZN

185.18

-0.81%↓

LLY

1,006.74

-1.12%↓

JNJ

229.99

-0.1%↓

ABBV

210.58

+1.02%↑

UNH

400.55

-0.16%↓

AZN

185.18

-0.81%↓

Home・Listă Acțiuni・Fate Therapeutics Inc

Fate Therapeutics Inc

Deschisă

SectorSănătate

1.93 -2.53

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

1.94

Maxim

2.19

Indicatori cheie
By Trading Economics
Venit	-124K -32M
Vânzări	-372K 1.4M
EPS	-0.27
Marjă de profit	-2,364.792
Angajați	161
EBITDA	-13M -42M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+108.41% upside

Dividende
By Dow Jones
Următoarele câștiguri	10 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	79M 253M
Deschiderea anterioară	4.46
Închiderea anterioară	1.93

Sentimentul știrilor

By Acuity

73%

27%

307 / 346 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

0.9101 / 1.14 Suport & Rezistență

Fate Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

13 mai 2026, 22:54 UTC

Câștiguri

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 mai 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 mai 2026, 23:51 UTC

Market Talk

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 mai 2026, 23:45 UTC

Market Talk

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 mai 2026, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

13 mai 2026, 23:17 UTC

Câștiguri

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 mai 2026, 23:16 UTC

Câștiguri

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 mai 2026, 23:15 UTC

Câștiguri

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 mai 2026, 23:14 UTC

Câștiguri

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 mai 2026, 23:02 UTC

Market Talk

Câștiguri

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 mai 2026, 22:59 UTC

Market Talk

Câștiguri

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 mai 2026, 22:24 UTC

Câștiguri

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 mai 2026, 22:23 UTC

Câștiguri

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 mai 2026, 22:23 UTC

Câștiguri

Xero FY International Revenue Growth 47%>XRO.AU

13 mai 2026, 22:22 UTC

Câștiguri

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 mai 2026, 22:19 UTC

Câștiguri

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 mai 2026, 22:19 UTC

Câștiguri

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 mai 2026, 22:18 UTC

Câștiguri

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 mai 2026, 22:16 UTC

Câștiguri

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 mai 2026, 22:15 UTC

Câștiguri

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 mai 2026, 22:15 UTC

Câștiguri

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 mai 2026, 22:13 UTC

Câștiguri

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 mai 2026, 22:12 UTC

Câștiguri

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 mai 2026, 22:11 UTC

Câștiguri

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 mai 2026, 22:11 UTC

Câștiguri

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 mai 2026, 22:10 UTC

Câștiguri

Xero Did Not Declare a Dividend>XRO.AU

13 mai 2026, 22:10 UTC

Câștiguri

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 mai 2026, 22:09 UTC

Câștiguri

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 mai 2026, 22:00 UTC

Câștiguri

Cisco to Shed Jobs for All-In AI Push -- Update

13 mai 2026, 21:11 UTC

Câștiguri

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Comparație

Modificare preț

Fate Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

108.41% sus

Prognoză pe 12 luni

Medie 4.46 USD 108.41%

Maxim 7 USD

Minim 2 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruFate Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

7 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 7 analiști care au acordat evaluări ale acțiunilor Fate Therapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

0.9101 / 1.14Suport & Rezistență

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

307 / 346 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.